Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dequalinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dequalinium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Vaginosis, Bacterial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : Dequalinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dequalinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vablys® (dequalinium chloride vaginal tablets), is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women under 55 years of age.
Product Name : Vablys
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Dequalinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable